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ABSTRACT 
 
 
The well-known regulatory function of microRNAs seems to play an important role in 
disease mechanism. Recent hypotheses have positioned them as a promising option for 
the study of genetic disorders. In this context, the microRNA profile of three 
phenotypically related rare genodermatoses, namely Recessive Dystrophic 
Epidermolysis Bullosa, Kindler Syndrome and Xeroderma Pigmentosum type C, is 
going to be analyzed taking as a reference healthy controls within the frame of  network 
medicine concepts. Bioinformatics tools have proven to be essential to keep track of the 
alteration of the dysregulated microRNAs all over the organism. This thesis provides a 
direct correlation between the real and observable symptoms of the three conditions and 
the distortion at molecular level caused by pathogenic pathways. From the network 
analysis and functional enrichment analysis, a small selection of microRNAs and target 
genes are proposed as potential candidates for further research. Thus, with this project, 
it becomes evident the need of powerful predictive research tools previous to laboratory 
validation. In the considerably new field of microRNAs, the design and elaboration of 
more precise treatments as well as the discovery of biomarkers for early detection 
prevail among the possible different applications. 
 
Keywords: Bioinformatics, network science, microRNAs, Recessive Dystrophic 
Epidermolysis Bullosa, Kindler Syndrome, Xeroderma Pigmentosum type C 
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1. INTRODUCTION 
 
1.1. Medical background 
The human body is constituted by thousands of cellular components that interact among 
them giving raise to specific functions. All these interactive pathways are collectively 
known as the human interactome [1]. 
 
Interactome network-based dependencies comprise undoubtedly a massive amount of 
data to be considered as complex systems. Network science arose at the beginning of 
this century to face the challenge of studying and analyzing whole interconnected 
systems, viewed as integrated networks. The spotlight is now on understanding the 
collective, holistic behavior instead of the reductionist analysis of the individual 
system’s components. A firm knowledge of the assembly principles present in any 
network appears to be the key for a correct interpretation of such an intricate 
entanglement [2]. 
 
The recent revolution concerning computational analysis has motivated the emergence 
of network maps and bioinformatics tools have resulted crucial to deal with the 
processing of data obtained from them. In the big data actual scenario, driven by omic 
technologies in the biomedical field, computing algorithms have undoubtedly surpassed 
human abilities in terms of speed of analysis and storage capacity [2]. 
1.2. Network medicine 
Medical research is focusing its efforts on the elucidation of genotype-phenotype 
relationship. Genetic disorders have been associated to abnormalities on particular 
genes. However, the link between the mutation and the resultant phenotype is not 
straightforward as the Beadle and Tatum’s hypothesis “one gene/one enzyme” 
suggested. Even identical genotypes under the same environmental conditions may 
result in different phenotypes. Further investigations towards these lines would provide 
decisive clues to reveal the great enigmatic mechanism behind human diseases [3][4]. 
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The complex interactome network may explain why the phenotypic signs of a disease 
are not uniquely the result of a damaged gene but the breakdown of the interrelation of 
that particular gene with all its surroundings molecules - direct interactors. A 
perturbation on the interactome implies that multiple processes functionally associated 
become altered. Consequently, diseases appear externally as a clinical frame of diverse 
pathological signs and symptoms usually influencing different systems of the organism 
[1]. 
 
Until now, the diagnosis of illnesses has been based on the hopefully fortunate 
recognition of a known classified group of clinical manifestations by physicians. The 
posterior treatment is then focused on palliating the symptoms. In this context, a new 
concept of medicine is emerging, the so-called network medicine, that draws the 
attention to the identification of disease modules. In the clinical practice, it supposes a 
complete twist of the screw, seeking for the root of the defect instead of the 
consequences [1][4]. 
 
Understanding a disease from a network-minded perspective implies to go back to the 
genetic origin and trace the biological routes that lead to the external perceptible 
symptoms. 
1.3. Network principles applied to human disease 
It might be thought that the first approximation to find the origin of a disease would be 
to identify the genes involved in the condition. It is not an easy task indeed if we 
consider that only 10% of the total human genes have a recognized disease-association 
[1]. Furthermore, even in the cases when the causal genes are known, there are 
intrincate and complex gene-phenotype relationships that must be understood in order to 
develop specific treatments for each disease. 
 
In order to approach this problem, the modus operandi of network medicine consists on 
localizing neighborhoods of interconnected nodes, responsible for a determined cellular 
function in the organism, and whose rupture defines the phenotypic characteristics of a 
particular disease. Only with a general overview of the interactions that give answers to 
the observable phenotype, it is possible to localize the “wire” (cause) that is not working 
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when an uncommon external manifestation from the inner malfunctioning is perceived 
(effect) [1]. 
In network theory, nodes that connect to many others and interact functionally with 
them are referred as “hubs” (Figure 1.1). In this sense, hub proteins (those proteins that 
are highly connected to others) seem to play a fundamental role in the propagation of a 
disease. The reason is that a great number of connections implies a higher impact on 
multiple functional associations. In fact, the encoding genes of hub proteins are believed 
to correspond mainly to essential genes. Mutations in them would impede early 
development and provoke the spontaneous death of the embryo. However, in some 
cases, the mutation is tolerated, the embryo survives but shows more phenotypic 
changes compared to the model organism, resulting in a heritable disease [1][3].  
 
          
Figure 1.1. Illustration of network concepts. Source: [5] 
Recent studies have proven that diseases with similar phenotypes share, to a greater or 
lesser extent, the connectivity patterns of their disease modules. As time passes by and 
research goes on, it has been assumed that diseases cannot be considered as independent 
from a molecular point of view. The overlap of disease modules explains comorbidity 
and phenotype similarity among certain conditions [1]. 
 
Global disease network maps have emerged to represent the dependency of diseases 
with known common molecular mechanisms or symptoms[3]. In the human diseasome, 
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two diseases are linked if they have in common at least one genetic component [6]. The 
establishment of such connections supposes a significant step in the search of genotype-
phenotype associations. In fact, it has been proven that not only does a correlation exist 
between disorders with similar symptoms and common genes but also the proteins 
encoded on those genes tend to interact more among them [4][7]. Therefore, as a direct 
consequence, a great majority of the same pathways will be altered in these cases.  
 
1.4. Genodermatoses under study 
In human beings, genetic information is contained in 23 pairs of chromosomes. The last 
pair is the one that determines the sex of the individual. The rest of pairs receive the 
name of autosomes. Genes are small fragments that occupy a determined location 
within each chromosome. Genetic disorders arise from mutations on specific genes that 
are inherited from parents to children. Depending on the inheritance pattern, inherited 
diseases are classified as dominant, if the mutation only affects one copy of the pair of 
chromosomes or recessive, if both copies present the gene mutated. Besides that, a 
disease is considered rare when is suffered by less than 5 people out of every 10,000 
inhabitants. There are estimated to be around 7,000 rare diseases affecting the 7% of the 
world population. According to Federación Española de Enfermedades Raras (FEDER), 
the number of people affected in Spain exceeds 3 millions [8]. 
 
Herein, three rare autosomal recessive diseases are presented. The reason why they have 
been grouped for this study is that, despite their different genetic background, they share 
similar phenotypic characteristics; among them, it is worth mentioning a strong 
tendency to develop cell carcinoma at the squamous cells of the epidermis. 
1.4.1. Recessive Dystrophic Epidermolysis Bullosa (RDEB) 
Epidermolysis Bullosa (EB) is an inherited disorder mainly characterized by the 
appearance of a blistering pattern in the skin. Given its genetic origin, EB is caused by 
mutations on specific genes that impede the correct expression of groups of proteins 
responsible for the adherence of epidermis to dermis (Figure 1.2) [9].  
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Figure 1.2. Representation of skin layers. Source. [10] 
Attending to the type of proteins lacking, EB is classified in four main types (Table 
1.1): 
TABLE 1.1. TYPES OF EPIDERMOLYSIS BULLOSA. Source:[11] . 
  EB type  Lacking proteins Level of detachment  
 
EB simplex (EBS) 
 
Keratins 5 and 14 
Plectin 
 
In the epidermis 
 
Junctional EB (JEB) 
 
Laminin 5 (now 332) 
Collagen XVII 
Integrin α6β4 
 
In the lamina lucida 
 
Dystrophic EB (DEB) 
 
Collagen type VII 
 
In the sublamina densa 
 
Kindler Syndrome (KS) 
 
Kindlin 1 
 
Any layer 
 
For the diagnosis, immunofluorescence mapping by antigen staining is a technique 
widely used to classify the type of EB from a skin biopsy of the blistering area (Figure 
1.3) [12]. The last known figures concerning EB estimate that there are between 50.000 
and 80.000 cases in Europe and around 2.000 in Spain [13]. In order to have an official 
approximation of the prevalence of DEB, it is necessary to go back to the conference of 
Spain RDR in December 2014. By that date, a 70% of the 69 patients included in the 
EB Registry in Spain had been diagnosed with the dystrophic type of the disease [14]. 
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      Figure 1.3. Scheme of the level of damage of the different types of EB. Source:[15] 
Two patterns of inheritance can be distinguished in the Dystrophic EB: dominant 
(DDEB) and recessive (RDEB). RDEB is associated to a mutation on the gene 
COL7A1, responsible for the production of collagen type 7. This protein serves as the 
major constituent of the anchoring fibrils that joins the sublamina densa of the basement 
membrane to the dermis [11][12]. 
People suffering from RDEB show an increased fragility of the skin and suffer from 
complications in the mucous membranes, especially affecting the eyelids or oral cavity 
as well as the respiratory, esophageal and intestinal tracts. In the most severe cases, the 
disease may lead to an early death (before the age of 30) usually due to the outbreak of 
renal problems or the high risk to develop carcinoma [12][16]. 
1.4.2. Kindler Syndrome (KS) 
Kindler Syndrome (KS) is the most singular and unusual type of Epidermolysis Bullosa. 
In the same way as the previous mentioned RDEB, patients with KS also present skin 
blisters. It is characterized by the loss of the structural protein Kindlin-1, caused by the 
mutated form of the FERMT1 encoding gene [17]. The distribution statistics presented 
at the conference of Spain RDR in December 2014 stated a 1% of KS in the 69 
registered patients with EB in Spain [14]. 
From its definition as syndrome by Theresa Kindler in 1954, numerous papers and 
articles have been published reporting cases of people affected all over the world 
[18][19][20]. Affected individuals coincide in a high photosensitivity and fragility of 
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the same damaged tissues in RDEB. Proof of this is that some publications refer to the 
skin of these patients as cigarette paper- like skin. The symptom picture is quite similar 
to the previous genodermatosis described.   
 
However, the aggressive phenotype that the disease presents cannot be uniquely 
explained by a genetic mutation, especially the clinical features not related to direct skin 
damage such as photoaging or the higher propensity to develop cancer. In a recent 
study, Zapatero-Solana et al., suggested oxidative stress to be a major factor in the 
general derangement of the organism in KS. Loss of function in kindlin-1 seems to 
disrupt several signal transduction pathways in which integrins and focal adhesions take 
part [21]. 
 
A more abundant generation of reactive oxygen species (ROS) imbalance the redox 
status and harm the genetic material. As a defense, the mechanisms responsible for the 
detoxification are activated to produce antioxidant molecules, such as glutathione, in an 
attempt to recover the equilibrium. Keratinocytes from KS patients show aberrant-
shaped mitochondrias and a clear pro-oxidant state: a greater ratio between oxidized and 
reduced glutathione (GSSG/GSH), the downregulated expression levels of gamma-
glutamyl cysteine ligase (GCLC and GCLM) which accelerates the synthesis of GSH 
and an increased amount of malondialdehyde (MDA), a known degradation product 
from ROS reactions (Figure 1.4) [21]. 
 
 
 
 
 
 
 
 
Figure 1.4. Results obtained in an experiment with KS keratinocytes. 
Source: [21].  
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1.4.3. Xeroderma Pigmentosum complementation group C (XPC) 
The malignancy of Xeroderma Pigmentosum (XP) disorder is attributed to mutations on 
eight genes related to the nucleotide excision repair (NER) pathway that serves as a 
redress mechanism for the damage caused by UV light on DNA (Figure 1.5). The 
different types of the disease are named according to the gene affected. In the case of 
XPC, the gene mutated is XPC involved in the recognition of photoproducts in DNA 
[22]. The prevalence of XP in Europe have been established in 1 person per 250.000 
inhabitants [23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In more than half of the cases, even a brief exposure to sunlight causes severe sunburns, 
giving rise to a characteristic pattern on the skin with different level-of-pigment patches 
and blisters. The remaining cases progressively develop anomalous excessive freckle-
like pigmented lesions (lentiginosis) on sun-exposed areas. Only a quarter of the 
diagnosed XP patients in US incur in neurological complications that seriously 
aggravate their quality of life. Symptoms usually appear since the early infancy and, as 
the other genodermatoses, XP patients have an elevated tendency to develop 
carcinogenesis [24].  In fact, according to FEDER, XP patients have a 1,000 times 
increased risk of suffering skin cancer than the rest of the population [25]. 
Figure 1.5. Scheme of the NER pathway. Source: [24]. 
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1.5. MicroRNAs  
On the basis of the above, the new “think globally – act locally” perspective to handle 
with the cure of a disease is being directed towards comprehending in deep the 
mechanisms of diseases so that a satisfactory treatment can be implemented. 
Nevertheless, as drugs need to be targeted to a specific point, key intermediary-
pathways players must be accurately localized. In this context, microRNAs have 
emerged as a promising option. 
 
The recently discovered microRNAs (miRNAs) molecules have groundbreakingly 
adopted a privileged place in biomedical research. These small non-coding RNA 
(ncRNA) molecules of 18-25 nucleotides modulate gene expression post-
transcriptionally and are present in almost every metabolic pathway in the organism. 
Due to their regulatory activity, they have attracted considerable interest in the study of 
diseases. They might be the triggering agents for the disease cascade in the human 
interactome, and thus, the ultimate responsible for the pathogenesis of diseases [26][27]. 
 
Although this thesis will be focused entirely in miRNAs, the reader should also know 
that there exists a different variety of ncRNA molecules including: transfer RNA, 
nucleolar RNA, nuclear RNA, phage and viral RNA, small interfering RNA (siRNA) or 
PIWI-interacting RNAs (piRNAs) among others [28].  
1.5.1. Discovery of miRNAs 
In 1993, lin-4 was identified at Dartmouth Medical School as the first miRNA in 
Caenorhabditis elegans, a nematode species. The original RNA was not translated into 
proteins as expected but instead it was divided in small transcripts [26][29]. 
 
The very same year another research group from Harvard Medical School shed light on 
the functionality of these short fragments. They confirmed the antisense base-pairing 
between the lin-4 miRNA and lin-14 messenger RNA (mRNA). This mRNA, declared 
afterwards the first target gene of a miRNA, was surprisingly repressed due to the 
complementary binding [26][29]. 
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However, the spotlight started to be focused on this area when in 2000, the second 
miRNA discovered, let-7, was proven to have been perfectly conserved throughout 
evolution during hundreds of millions of years. Since this moment, there was a 
spectacular progress in the search of new miRNAs [26][29]. 
 
1.5.2. Biogenesis of miRNAs 
The central dogma of biology states the directionality of genetic information from DNA 
material (Figure 1.6). However, it is being questioned nowadays due to the non-coding 
RNAs (ncRNAs) molecules. The predecessor DNA fragments of ncRNAs undergo 
transcription but do not fulfill the translation step. Therefore, the final function of these 
types of RNAs is not structural (to conform a protein) but regulatory [30]. 
 
Figure 1.6. Representation of central dogma of biology. Messenger RNA is created 
after transcription, which is then translated to proteins. Source:[30] 
The exact mechanism of action of miRNAs is not yet fully understood and many 
aspects remain still unclear [7]. Nevertheless, until now, it is believed to happen as 
follows (Figure 1.7) [28][31][32]: 
1. Transcription of the genome generating a long precursor RNA molecule, 
primary miRNA (pri-miRNA) and normally mediated by the enzyme RNA 
polymerase II. 
This pri-mirna is characterized by a hairpin, a cap and a poly A tail. 
2. Recognition of pri-miRNA structure by the nuclear RNAse III enzyme Drosha 
and its cofactor DGCR8/Pasha (all of them form a complex known as 
Microprocessor) with the subsequent cleavage of pri-miRNA that gives rise to 
the precursor miRNA (pre-miRNA) of 70 nucleotides. 
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3. Translocation of pre-miRNA from nucleus to cytoplasm via Exportin-5 
4. Processing (second cleavage) by another RNase III enzyme, Dicer, to form 
mature miRNA duplexes (double-stranded miRNA/miRNA*) of approximately 
22 nucleotide length  
5. Loading of the mature strand of the miRNA duplex into the RNA-induced 
silencing complex (RISC) facilitated by Argonaute proteins. Finally, they jointly 
target specific mRNAs, mainly at the 3’ untranslated (UTR) region, to produce 
translational repression or mRNA degradation, depending on the level of 
complementarity between bases.  
 
1.5.3. Role of miRNA in diseases 
The mechanism of action of miRNAs remains still in question. At the beginning, it was 
said that miRNAs were involved in the post-transcriptional regulation of mRNAs at the 
cytoplasm. However, recent studies open up the possibility of their implication at the 
nuclear level leading to alternative splicing [31]. 
 
Be that as it may, there is strong evidence that dysregulation, either up or 
downregulation, of some miRNAs is behind human malignancies, and in particular, 
Figure 1.7. Scheme of biogenesis of miRNAs. Source: [61] 
12 
 
behind cancer development. Either by overexpression, repression or deletion of the 
RNA targets, tumorigenesis is caused in one or other way [33]. 
 
Although, the identification of miRNA-mRNA target interactions is still going on, there 
is great hope in employing miRNAs in the theranostics field. They have been proposed 
as potential drug targets to reverse gene expression of diseases, or even, synthetic 
miRNAs that could replace the malfunctioning ones [26]. 
 
Along this thesis, the miRNA-RNA interaction network modules overlapping in three 
genodermatoses is going to be analyzed. 
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2. HYPOTHESES AND GOALS 
 
The similarity in certain phenotypical characteristics of Recessive Dystrophic 
Epidermolysis Bullosa (RDEB), Kindler Syndrome (KS) and Xeroderma Pigmentosum 
type C (XPC) raise the curiosity of finding shared altered regulatory mechanisms. 
Network medicine has appeared as a tool to relate the biological compounds in disease 
modules with successful targeted treatments. The ambitious objective of finding the 
cure to a genetic disease must accept the fact that mutations themselves do not give a 
complete explanation to all the phenotypical features observed.  
 
Until the present day, no publications have been issued covering the phenotypical 
resemblance of these three diseases. Subsequently, any research towards this direction 
enters a completely unexplored area. However, given the overlap in symptomatology, 
there are huge expectations on the discoveries that could be made from a molecular-
level network analysis.  
 
A pioneering study [34] carried out by UC3M Bioengineering Department along with 
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IISFJD), Centro de 
Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro 
de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) have provided 
source data to start with this thesis. The RNA sequencing (RNA-Seq) analysis 
performed on fibroblasts from RDEB, KS, XPC patients and healthy donors, provided 
raw data of miRNA to be analyzed. Fortunately, remarkable conclusions were achieved 
at RNA level: the three disorders shared 227 transcripts and 42 signaling circuits 
altered. Certainly, once common molecular pathways were proven to exist, a promising 
horizon in miRNA analysis started to be glimpsed. The starting point in this thesis is, 
therefore, the treatment of the available miRNA data to throw light on disease common 
mechanisms, and with the following goals in mind: 
 
 Extract the common dysregulated microRNAs to the three conditions taking as 
reference healthy controls. 
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 Find enriched functions in which the miRNAs of the previous point are 
implicated. 
 Study the RNA target molecules through an interaction network. 
 Select miRNAs candidates potentially useful as therapeutic targets. 
15 
 
3. MATERIALS AND METHODS 
 
3.1. Data collection 
Next generation Sequencing (NGS) is related to all the novel high-throughput platforms 
that are able to sequence nucleotide chains (both DNA and RNA). Nowadays, for RNA 
profiling, the most widely–used technique is RNA-Sequencing (RNA-Seq), a NGS 
method that is able to detect both coding and non-coding RNAs. Although there are 
three main NGS platforms that perform the sequencing step, Illumina HiSeq, Ion 
Torrent and SOLiD system, the general protocol is the same for all three. First, RNA is 
isolated from the tissue of interest and a quality control is carried out to correct possible 
defects from the signal acquisition procedure. Then, RNA samples are fragmented in 
small pieces and they undergo reverse transcription to form double-stranded 
complementary DNA (cDNA). During this library preparation step, adapters are also 
added to be ligated to both ends of the fragments and PCR amplification is 
implemented.  Depending on the platform used, the characteristics of the adapters vary 
as well as the mode of reading the sequence. Anyway, the number of reads that aligns to 
a transcript (counts) is returned as output, and in RNA-Seq is then related to the amount 
of expression (quantity of reads) of the RNA. A statistical analysis is usually made 
afterwards to provide further information such as the level of expression compared to 
control samples or the p-value for evaluating the significance of the results [35]. 
Our bioinformatic analysis started with the miRNA counts coming from fibroblasts of 
eighteen subjects: nine RDEB patients, three KS patients and three XPC patients, taking 
as reference three healthy donors [34].  
3.2. Data treatment 
The real challenge of omic technologies is to know how to interpret the massive amount 
of information obtained from high-throughput techniques. An exhaustive bioinformatic 
data processing is necessary to translate numbers, variables and parameters to an 
understandable biological meaning. Furthermore, the validity of any research findings is 
closely related with the way the analysis of the information is geared. The action plan 
for this thesis has been carefully designed to arrive to conclusions that can guide future 
lines of research. 
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3.2.1. Understanding source data 
For each one of the genodermatoses, raw data consisted on the list of miRNAs 
expressed (almost a thousand) along with information relative to its comparison with 
the control group: 
 miRNA name: it corresponds to the identifier given by miRBase [36], at the 
moment of its incorporation to the database. More details are given hereunder. 
 logFC: means log fold-change and gives a clue about how much absolute 
change exists in a specific variable between two measurements. In this case, the 
fold change is calculated by dividing the average read counts of the disease 
condition by the average read counts of the healthy control. Then, the sign tells 
us if there is overexpression (when positive) or underexpression (when 
negative). 
 logCPM: stands for log counts per million and it also provides information to 
compare expression levels between groups. 
 p-value: expresses the level of certainty of an existenting difference. By 
convention, a result is considered statistically significant when the p-value is 
lower than 0.05.  
 FDR: stands for false discovery rate. The FDR approach serves to reduce the 
number of false positives. It can be used as a corrected p-value that takes into 
consideration the great number of variables with respect to the number of 
samples analyzed. FDR is going to be used in this analysis given the high 
amount of miRNAs in comparison with the small number of subjects. 
 
miRBase (Figure 3.1) [36] is the world reference database where all miRNAs are 
registered. Not only the sequence but also annotations associated to each molecule can 
be found.  
Figure 3.1. miRBase [36] interface. 
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miRBase [36] has established the official nomenclature to be followed for the 
introduction of any miRNA in the repository. The format consists on these four 
elements separated by hyphens:  
-  Three initial letters that refer to the organism. In our case, these will 
always be “hsa” as we are going to focus just on the Homo Sapiens 
species. 
- Three following letters, which can be either “mir” regarding the 
miRNA gene or “miR” for the mature miRNA and in some 
exceptional cases, “let” and “lin” due to historical reasons. 
- A number that is assigned sequentially according to the order of 
discovery. 
- Posterior lettered suffixes are added in some cases to distinguish 
similar sequences with different precursors or from opposite arms. 
The deposition of new miRNAs in miRBase [36] has grown exponentially in the last 
years, achieving a total of 38589 entries on March, 2018 [36]. 
3.2.2. Comparison of data groups 
Given the volume of data, it is essential to narrow the field of possibilities just to the 
most relevant ones ignoring non-meaningful data. Following these guidelines, the first 
obvious step is to know which significant miRNAs are shared by the three 
genodermatoses under study. To accomplish this task, Venny (Figure 3.2) [37] has 
consolidated as an exceptional option. 
Figure 3.2. Venny [37] interface. 
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This program offers a clear graphical comparison of different group categories. It 
receives as input a maximum of four lists of elements. As a result, a figure with 
overlapping circular diagrams is drawn on the screen, commonly known as Venn 
diagram, in which each circle represents one list. Percentages at the intersections can be 
shown to assess the level of similarity between circles. Attributes such as style, format 
or color can be changed depending on one’s preferences. 
3.2.3. Analysis of interactions 
The study of the interactions of miRNAs results crucial to understand their role in the 
organism. The interface of miRNet (Figure 3.3) [38] platform enables the integration of 
data in networks to visualize the relationships among known-sequence molecules and its 
targets. 
 
A network can first inspire respect because of its complexity. However, it is important 
to keep in mind the simple definition of networks: they are just nodes connected by 
links. Taking advantage of the defined structure any grand network is based on, there 
are a set of useful tools that allow to explore them and find its most influential elements: 
 
Figure 3.3. miRNet [38] interface. 
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 The degree of a node will indicate which nodes have a greater number of 
edges or, in other words, the number of connections to other nodes. Hubs 
(nodes with a high degree) seem to be key participants in diffusion 
processes. Thus, they are also considered important in this study where 
diseases are seen as spreading events affecting a variety of functions in 
the subject. 
 The betweeness of a node has a lot to do with connectedness. Those 
nodes that are present in most of the connecting paths between two 
nodes, will show a high value for betweeness. If these interconnective 
nodes are somehow altered, the connections between modules in the 
network will fail or at least not be produced in the same way as in normal 
conditions. Betweeness should also be an important parameter of study.  
 Clustering could also attract attention in the analysis of diseases. It is not 
an individual property of a node but instead it looks at the neighbors of 
the node. Clusters could explain related mechanisms (modules) to be 
altered in a particular disease.  
 
The miRNet [38] program works in three main steps: 
i. Data upload and processing: It gives the possibility of entering diverse type of 
data from lists of miRNAs, transcripts or small molecules to tables from RNA-
Seq or microarrays. 
ii. Network creation and refinement: An interaction network is generated. By 
default, input molecules appear as red circular nodes and target molecules as 
light blue squares, all of them linked by white edges over a black background, 
although sizes and colors can be easily modified. Several functionalities are 
available to transform huge networks in simpler ones depending on the aim of 
the research. Deletion of nodes/edges or filtering by degree, betweeness or 
shortest path are some of the options that help in the controlled reduction of the 
network.  
iii. Network analysis: miRNet [38] also has a functional analysis panel to perform a 
functional enrichment analysis (see below). This allows a further in-deep 
analysis of the biological pathways associated to the network selected. Different 
databases such as Gene Ontology (GO) [39], Kyoto Encyclopedia of Genes and 
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Genomes (KEGG) [40] or REACTOME [41] are consulted to seek for the 
functions affected. 
3.2.4. Functional enrichment analysis 
It is widely believed that genetic disorders are intrinsically linked to an overexpression 
or underexpression of certain genes in comparison with normal controls. These are 
called differentially expressed (DE) genes and stand as highly probable candidates of 
being involved in the disease (either its generation or the phenotypical outcome).  
In the same way, miRNAs will be considered determinant for the disease, if they are 
differentially expressed (with respect to healthy controls). The relationship between DE 
miRNAs and DE genes arise a curious phenomena that could help us in the 
prioritization of miRNAs. The concept is that if the miRNA is overexpressed, and 
considering that they usually negatively regulate the expression of coding RNA, it 
would mean higher inhibition of the genes than in normal conditions. Therefore, 
regulated genes in this case may appear underexpressed. And the opposite may happen 
if the miRNA is underexpressed. 
However, more than just knowing the nomenclature of the genes, the real interest 
ultimately lies on discovering the functional role of the genes affected. Once again, 
bioinformatics facilitates this task by making an automatic search of annotations 
(functions or pathways) related to a particular gene and enclosing under the same 
concept genes that share similar annotations. A functional enrichment analysis therefore 
provides those functions or pathways that are statistically relevant (and consequently 
have a small p-value) in a list of genes, that can come from a list of miRNA targets. 
These functions can be established in terms of the place where the genes are active 
(cellular component), the activity or specific function in which the genes are implicated 
(molecular function) or the biological pathway to which the genes contribute (biological 
process), and are annotated in the Gene Ontology (GO) Database [39], or others such as 
KEGG [40] or Reactome [41]. 
From all the enriched functions, the interest focuses normally on those that include a 
greater number of DE genes, or those with smaller p-value, due to the again difficult 
task of extracting meaningful information from large lists of data. REViGO (Figure 3.4) 
[42] defines itself as the tool to summarize an extended enumeration of Gene Ontology 
(GO) terms. When a great amount of hits are returned, it is quite useful to just rescue the 
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most significant outcomes and ignore the rest, or group them together into relevant 
groups. GO terms are approved wording expressions to design specific features 
occurring in biological systems. REViGO [42] analyzes a list of GO terms with assigned 
p-values and gives as a result the highlighted pathways or elements for each category: 
molecular function, cellular component and biological process. 
3.3. Data selection 
After all the steps, the analysis should conclude with the most remarkable miRNAs. The 
idea is to make a selection of a small group of miRNAs that could serve as biomarkers 
for diagnosis or targets for treatment. Hopefully, it is possible to delimit the initial 3.000 
miRNAs field to just some miRNAs that exhibit evidence or at least clear objective 
clues to be partially responsible of the common disease mechanism hidden behind 
RDEB, KS and XP. 
Figure 3.4. REViGO [42] interface. 
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4. RESULTS 
 
4.1. Analysis of the dysregulated microRNAs in diseases vs. controls 
As it has been exposed above, the expressed miRNAs from RDEB, KS and XP patients 
had been identified by the RNA-Seq experiment. The data consisted on the list of 
miRNAs names in Excel format with the statistical parameters of logFC, logCPM, p-
value and FDR. Healthy controls were taken as reference.  
The original list gave a total of 1252/964/891 miRNA outcomes in RDEB vs. Healthy, 
KS vs. Healthy and XPC vs. Healthy respectively and was necessarily reduced by 
discarding miRNAs with a FDR higher than 0.05. The new list had 27/99/148 
components (Annex), figures quite more reasonable to work with. Table 4.1 
summarizes this reduction.  
 
 
These three short lists were first introduced in Venny [37] to obtain common and 
specific miRNAs for each condition (versus healthy controls). The results obtained can 
be seen in Figure 4.1. A considerable overlap among the three can be appreciated with a 
total of 18 significant DE miRNAs in common. 
TABLE 4.1. LISTS OF MIRNAS 
 #miRNAs 
RDEB vs. Healthy 
#miRNAs 
KS vs. Healthy 
#miRNAs 
XPC vs. Healthy 
 
Total miRNAs 
detected 
 
 
1252 
 
964 
 
891 
Significant 
miRNAs 
(FDR<0.05) 
 
27 
 
99 
 
148 
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The hypothesis at this point is the following: shared miRNAs might justify the 
similarities between the diseases, while specific miRNAs in each condition would 
account for the differences. In this thesis, the analysis has been made primarily with the 
miRNAs shared by the three conditions, in order to try to find an explanation to the 
phenotypical resemblance.  
 
The eighteen miRNA names are listed in Table 4.2, with an arrow next to it indicating 
the change of expression compared with control. The pointing-up arrow represents 
overexpression and in the opposite direction, it means underexpression. Surprisingly, it 
was possible to establish an up or down arrow for each miRNA because in the three 
comparisons the direction of change in expression is the same. 
 
 
 
 
Figure 4.1. Venn diagram of the significant miRNAs. 
24 
 
 
 
Furthermore, it is worth mentioning that the absolute difference of the change almost 
coincides numerically in the three.  The scatter plot of Figure 4.2 represents in Cartesian 
coordinates the relationship among the log FCs. Each axis corresponds to the data from 
one genodermatosis vs. control. The diagram shows a clear positive correlation for each 
pair of diseases. The pattern of blue dots approximately adjusts to the identity line so it 
can be confirmed that the three genodermatoses change following the same trend in 
growth. 
miRNAs logFC(RDEB vs Healthy) logFC(KS vs Healthy) logFC(XPC vs Healthy) 
hsa-miR-10a-5p  (↑) 8.82 10.50 10.44 
hsa-miR-10a-3p (↑) 8.59 9.54 9.48 
hsa-miR-556-5p (↓) -4.54 -6.28 -4.17 
hsa-miR-6507-5p(↓) -4.78 -5.37 -6.47 
hsa-miR-6842-3p(↓) -2.42 -2.77 -3.31 
hsa-miR-195-3p (↑) 2.90 2.01 2.36 
hsa-miR-129-5p (↑) 3.60 3.58 4.00 
hsa-miR-615-3p (↑) 2.97 3.24 3.64 
hsa-miR-129b-2-3p (↑) -2.15 -2.10 -1.71 
hsa-miR-29b-2-5p  (↓) 4.38 5.14 5.15 
hsa-miR-10b-5p (↑) 4.18 4.93 4.99 
hsa-miR-10b-3p (↑) -3.01 -4.68 -5.67 
hsa-miR-1295a (↓) 3.92 3.25 3.47 
hsa-miR-148a-5p (↑) 2.11 2.01 1.53 
hsa-miR-195-5p (↑) 2.55 2.93 3.15 
hsa-miR-629-3p (↑) 1.97 1.89 1.51 
hsa-miR-148a-3p (↑) 2.07 2.28 2.19 
hsa-miR-1468-5p(↓) -2.01 -3.59 -3.25 
TABLE 4.2. LEVEL OF EXPRESSION OF THE SHARED DYSREGULATED MIRNAS. 
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Figure 4.2. Scatter plot of the logFC of the 18 shared miRNAs.  
4.2. Analysis of the generated regulatory networks 
To really give sense to the arrows, the effect of the alteration must be verified by 
looking at the target genes that are being regulated by the 18 miRNAs. The interaction 
network was then implemented with the aid of miRNet [38]. 
The list with the eighteen elements was uploaded choosing the corresponding fields: as 
organism, H. Sapiens (human); as ID type, miRBase ID and as target type, genes. This 
is because the purpose is to investigate the genes regulated by the differentially 
expressed miRNAs and the functions of the organism that are consequently affected. 
One of the main problems faced when using databases is their incompleteness. Even 
more in the case of rare diseases, it is common not to find related terms. That was 
exactly the reason why the tissue field in miRNet [38] had to be left blank. When “skin” 
was selected, a reduction to almost null results was obtained due to the fact that only 2 
of the 18 miRNAs are reported so far in the miRNet [38] database for the skin category. 
Nevertheless, it was fortunate not to have closed the search to any particular tissue 
because interesting target genes present in other tissues may have not appeared. 
 
The network builder returned as overview details: 18 queries, 3295 nodes (miRNAs: 18, 
Targets: 3277) and 4200 edges. In the next step, it was possible to visualize the network 
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(Figure 4.3), a tangle of interconnected genes and miRNA, a scenario not especially 
accessible to deal with. However, predicting this, the program offers filter options to 
transform the network in an easy-to-use format to work with.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most important information that can be extracted from this network, in terms of 
degree of the nodes, is summarized in Table 4.3 and 4.4. The top-5 miRNAs (in terms 
of degree, Table 4.3) announce to be the main players in the network. They are 
regulating a great amount of transcripts so there is more probability for them to be 
involved in the disease cascade. On other side, the genes being regulated by a greater 
number of altered miRNAs (Table 4.4) might also attract our interest. Even if their 
regulating miRNAs show slight changes of expression, together may converge in a 
substantial difference in the target gene. 
 
 
 
 
Figure 4.3. Interaction network built from the eighteen predominant miRNA 
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4.2.1. Application of degree filter 
The degree of a node is defined as the number of edges it has to connect with other 
nodes. A hub is a node with a great number of connections compared to the rest. As it 
has been previously mentioned, hubs are liable to be related with the alteration of 
several and diverse functions in a diseased subject. 
 
In the list of results, ordered from highest to lowest degree, miRNAs occupy the first 
positions with their degrees oscillating between 893 and 17, and afterwards comes the 
genes. In fact, it is an obvious order of appearance if we take in consideration that the 
miRNAs have been forced to constitute the basis of the network, as it is a miRNA-target 
RNA network. In addition to this, dysregulated miRNAs seem to contribute notably to 
the disease signature and they have been proven to correspond to nodes with higher 
degree in a miRNA-genes network [43]. 
 
Pos miRNAs Degree 
1 hsa-mir-615-3p 893 
2 hsa-mir-195-5p 640 
3 hsa-mir-129-5p 625 
4 hsa-mir-10a-5p 463 
5 hsa-mir-10b-5p 323 
TABLE 4.3. MIRNAS WITH THE HIGHEST 
DEGREE IN THE GLOBAL NETWORK. 
Pos Genes Degree 
1 MTX3 5 
2 NR2C2 5 
3 CDK6 5 
4 ARL6IP1 5 
5 NPTX1 5 
TABLE 4.4. GENES WITH THE HIGHEST 
DEGREE IN THE GLOBAL NETWORK. 
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From the 3277 target genes,  
 
- 0.15% show degree 5 
- 0.73% have degree 4 
- 99.12% corresponds to genes with degree 3 and less.  
Low degree genes show fewer interactions which implies a weaker association to 
dysregulated miRNAs as well as a reduced susceptibility to be altered.  Hence, a degree 
filter is applied to eliminate from the map those genes with degree less than 4. The 
change in the network after the degree filter is quite illustrative (Figure 4.4). 
 
As a result, the network overview details showed lower values than before: 46 nodes 
(17 miRNAs and 29 targets) and 121 edges. Furthermore, the degree of all the nodes 
was obviously reduced. Now, the highest degree is 20. The miRNAs with higher degree, 
Table 4.5, are the same of Table 4.3 but in a different order. The genes with highest 
degree keep unchanged as expected. 
 
 
Figure 4.4. Interaction network after the application of the degree filter. 
29 
 
 
 
 
 
      
 
 
 
 
 
 
miRNet [38] offers the option of selecting the nodes of interest and extracting from the 
complete network the interactions affecting to those particular nodes. Figure 4.5 
illustrates the subnetwork obtained when hsa-mir10a-5p and hsa-mir-10b-5p, the 
highest degree miRNAs after the degree filter, were chosen. Eighteen genes are 
commonly regulated by these first two miRNAs. Following the degree order, when the 
third miRNA is added to the subnetwork, the number of common regulated genes is 
halved. If the fourth miRNA is introduced only 4 genes out of the initial 8 remain 
interconnected (Table 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 4.5. MIRNAS WITH HIGHEST DEGREE IN THE  
NETWORK ONCE THE DEGREE FILTER HAS BEEN APPLIED. 
Pos miRNAs Degree 
1 hsa-mir-10a-5p 20 
2 hsa-mir-10b-5p 18 
3 hsa-mir-195-5p 14 
4 hsa-mir-615-3p 14 
5 hsa-mir-129-5p 12 
TABLE 4.6. TARGET GENES SHARED BY THE MIRNAS WITH HIGHER DEGREE. 
GENE 1
st
 two miRNAs 1
st
 three miRNAs 1
st
 four miRNAs 
POU2F2 X   
Figure 4.5. Subnetworks extracted from the filtered network when selecting specific miRNAs. 
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If the four miRNAs with higher degree are effectively the most dysregulated, as 
presumable, the greater impact will be first noticed in their direct interactors. In this 
sense, FASN, HSPA1B, NR2C2 and KIAPP10 deserve to be highlighted for further 
research. 
 
On the other way around, different combinations of the genes with the higher degree 
lead to the miRNAs present in the top-5 after the application of the filter (Figure 4.6). 
The extent of these miRNAs is confirmed to be somehow distributed all around the 
network and in consequence, they stand as susceptible candidates for biological 
validation. 
 
 
 
 
 
 
 
XIAP X   
NPTX1 X   
TIMM50 X   
RUNDC3B X   
ONECUT3 X   
C3orf36 X X  
CSNK2A1 X   
MTX3 X   
BCL2L11 X X  
FASN X X X 
HNRNPF X   
HSPA1B X X X 
NR2C2 X X X 
RAPGEF2 X   
KIA0010 X X X 
ZNF460 X X  
SLC2A3 X X  
Figure 4.6. Subnetworks extracted from the filtered network when selecting specific miRNAs. 
31 
 
4.2.2. Functional enrichment analysis 
miRNet [38] also provides the opportunity to evaluate if any function is significantly 
enriched. The sample space is required to be sufficiently large to get significant results. 
That is why the functional enrichment analysis was only performed within the frame of 
the original network.  
The statistical method employed was a hypergeometric test and Reactome [41], the 
database where it looked for outcomes. Functional modules are validated through this 
algorithm by looking for common GO annotations on the gene network selected. As a 
result, 223 processes with an interesting biological meaning were shown, among which, 
it is worth highlighting the first hits (those with lower p-value) (Figure 4.7).  
 
Figure 4.7. Main significant functionally enriched Reactome pathways. 
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It can be stated that the results from the functional analysis are not random but keep a 
close relationship with concepts and ideas that have been exposed along the thesis and 
that are ultimately associated with the three genodermatoses of the study. In order to 
assess the dependency of the highlighted pathways, the genes involved for each process 
are compared to each other. Figure 4.8 is another network that serves us to explain the 
complementarity of the functions enriched. Venny [37] facilitated the counting as it 
returns the exact number of shared components in the overlapping sections of the 
diagram. The figures obtained are the ones that appear above the arrows of Figure 4.8 
connecting the related terms.  
It is possible to distinguish three main clusters around the main one (Gene Expression): 
- One cluster associated to cellular state, that englobes oxidative stress 
induced senescence, cellular senescence and cellular response to 
stress 
- Another one related to the transcription procedure (generic 
transcription pathway) 
- And, the last one related to the synthesis of RNA where mRNA 
splicing and processing of capped-intron containing pre-mRNA 
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Although the functional enrichment analysis is performed on the target genes, it is 
necessary to keep the link with miRNAs. In this sense, the targeted genes associated 
with each of the emphasized pathways were introduced as input in miRNet [38]. To 
limit the network, a manual batch filter was applied with the five miRNAs from Table 
4.3. 
Table 4.7 depicts the miRNA degree for each RNA-miRNA network. From the 
information of this table, it can confirmed that the five miRNAs regulate many of the 
genes implicated in the observable phenotypes of the diseases. 
TABLE 4.7. DEGREE OF THE FIVE SELECTED MIRNAS ASSOCIATED TO EACH ENRICHED PATHWAY. 
 
Genes involved in enriched pathways 
 
miRNAs 
 
Degree 
 
43 genes 
Oxidative Stress Induced Senescence 
hsa-mir-615-3p 14 
hsa-mir-195-5p 13 
hsa-mir-129-5p 10 
hsa-mir-10b-5p 6 
hsa-mir-10a-5p 5 
Figure 4.8. Network with the most significant functionally enriched pathways. 
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62 genes 
Cellular senescence 
hsa-mir-615-3p 20 
hsa-mir-195-5p 17 
hsa-mir-129-5p 12 
hsa-mir-10b-5p 8 
hsa-mir-10a-5p 6 
 
92 genes 
Cellular responses to stress 
hsa-mir-615-3p 34 
hsa-mir-195-5p 24 
hsa-mir-129-5p 16 
hsa-mir-10a-5p 16 
hsa-mir-10b-5p 11 
 
291 genes 
Gene Expression 
hsa-mir-615-3p 124 
hsa-mir-195-5p 58 
hsa-mir-10a-5p 49 
hsa-mir-129-5p 42 
hsa-mir-10b-5p 31 
 
74 genes 
Generic Transcription Pathways 
hsa-mir-615-3p 19 
hsa-mir-195-5p 18 
hsa-mir-10a-5p 14 
hsa-mir-10b-5p 13 
hsa-mir-129-5p 11 
 
53 genes 
Processing of Capped Intron-Containing 
Pre-mRNA 
hsa-mir-615-3p 36 
hsa-mir-195-5p 10 
hsa-mir-10a-5p 9 
hsa-mir-129-5p 7 
hsa-mir-10b-5p 4 
 
51 genes 
mRNA splicing 
hsa-mir-615-3p 35 
hsa-mir-195-5p 10 
hsa-mir-10a-5p 9 
hsa-mir-129-5p 6 
hsa-mir-10b-5p 4 
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4.2.3. Grouping of the functionally enriched pathways 
Even delimiting the study to the significant results (p-value < 0.05) that appeared in the 
functional enrichment analysis of miRNet [38], 223 hits continue to be an unmanageable 
quantity to draw conclusions from. Therefore, the program REViGO [42] was useful to 
classify and group the most relevant GO terms. 
 
miRNet [38] functional analysis returns the name of the pathways and the p-values. 
Once the hits with 95% of reliability (p<0.05) were differentiated and they were 
assigned its corresponding GO code, they were submitted to REViGO [42]. The 
outcome is then classified attending to the three categories of GO. The spotlight will be 
made on the category of biological processes (Figures 4.9 and 4.10). The greatest part of 
the resultant figure is referred to cellular senescence, followed by a still large area 
highlighting the oxidative single-stranded RNA demethylation and the last big group 
that forms part of the most representative pathways is gene expression. These are quite 
interesting terms that coincide with the literature of the three genodermatoses as will be 
thoroughly discussed in the next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Grouping of the most relevant biological process GO terms 
highlighted by REViGO. 
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4.3. Comparison with previous results 
This work was especially intended to continue the lines of research initiated by the 
RNA study of RDEB, KS and XP. Since the miRNA analysis was not started from 
scratch, it would be nonsense not to relate both studies in order to try to search common 
features and add additional findings to make progress. For these reasons, another 
approach consisted on seeking for the correlation among the 227 genes highlighted in 
the previous study and the 18 miRNAs of the actual one. A manual batch filter was 
applied to the original network so that target genes were inserted manually (Figure 
4.11). The new network connects 13 miRNAs with 36 targets (Figure 4.12). 
Figure 4.10. Grouping of the most relevant biological process GO terms 
highlighted by REViGO. 
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A pretty good point on the network generated is the presence of almost independent 
clusters. So in this graph, the significance of the nodes resides mainly in the betweeness 
(Table 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 4.8. MOST RELEVANT NODES IN THE FILTERED NETWORK. 
Pos Nodes Betweeness 
1 hsa-mir-10a-3p 462.33 
2 hsa-mir-615-3p 419 
3 HOXC4 375 
4 hsa-mir-195-5p 354.33 
5 TFAP2A 321.33 
6 VIM 256 
7 hsa-mir-129-5p 252 
8 HOXB3 175.33 
Figure 4.12. Interaction network after the 
application of the degree filter. 
Figure 4.11. Introduction of miRNA-target 
genes with the manual batch filter. 
38 
 
Furthermore, this comparison makes possible a deeper analysis in the relationship 
between altered miRNAs and altered RNA targets through their expression profile. 
When the RNA targets were unknown and miRNet [38] examined in its database the 
possible connections, the targets obtained lacked fold-change values. However, data of 
RNA targets was available from the previous study including logFC values.  
 
MiRNA-RNA interactions keep, in theory, an inversely proportional relationship [44]. 
Therefore, activation of a miRNA will imply loss-of-function in the genes connected to 
it and affected by such alteration. Therefore, genes whose expression levels do not 
respond to the theory exposed above imply that their different state of expression is not 
due to that particular altered miRNA. 
 
Table 4.9 represents the expression analysis performed. In order to establish a unique 
fold change value attributable to the three diseases, the median of the log fold change is 
calculated per gene. Yellow cells correspond to genes whose median log FC values tell 
us that the possible cause of their up/down-regulation may be generated by the miRNA 
they are associated to in the table. 
 
TABLE 4.9.ANALYSIS OF THE EXPRESSION PROFILE DEPENDENCY BETWEEN MIRNAS AND RNA TARGET GENES. 
miRNA Genes log FC (MEDIAN) RDEB KS XPC 
hsa-mir-195-5p 
+ 2.93 
BTG2 -2.254 -1.616 -2.254 -2.277 
TGFBR3 1.948 1.528 1.948 2.600 
TLE4 -1.691 -2.117 -1.691 -1.393 
TRAK1 1.363 1.213 1.363 1.401 
HOXC8 6.613 7.013 6.613 6.512 
SHOC2 1.809 1.433 1.809 1.821 
C1orf226 -4.820 -5.239 -4.820 -4.449 
CD2AP 1.817 1.653 1.817 1.866 
SLC29A1 -2.416 -2.416 -2.402 -2.615 
TFAP2A -3.635 -3.635 -3.410 -4.636 
hsa-mir-129-5p VIM 1.357 1.157 1.357 1.559 
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+3.58 VCAN 4.194 3.995 4.194 4.411 
KCNJ6 3.763 4.631 3.250 3.763 
L1CAM -5.724 -5.078 -5.724 -7.364 
ESR1 -3.656 -4.419 -3.656 -3.429 
LRRC2 3.445 3.609 3.445 3.411 
NR2F2 -1.753 -1.825 -1.753 -1.699 
DAB2 1.294 1.070 1.837 1.294 
hsa-mir-615-3p 
+3.47 
HOXC4 4.168 4.168 3.642 4.168 
SCARB1 -2.175 -1.960 -2.175 -2.471 
FN1 2.653 1.403 2.653 3.201 
VIM 1.357 1.157 1.357 1.559 
PTPRU -2.069 -1.657 -2.701 -2.069 
SYPL2 -6.553 -6.553 -3.808 -8.256 
CELSR1 -3.827 -3.521 -3.827 -4.999 
hsa-mir-10b-5p 
+5.14 
C1GALT1 2.159 2.047 2.159 2.336 
DLX1 4.285 4.081 4.401 4.285 
NEK7 1.837 1.782 2.511 1.837 
HOXB3 6.238 6.068 6.238 6.787 
hsa-mir-10a-3p 
+9.48 
TFAP2A -3.635 -3.635 -3.410 -4.636 
HOXC4 4.168 4.168 3.642 4.168 
CELSR2 -3.229 -3.157 -3.266 -3.229 
HOXB3 6.238 6.068 6.238 6.787 
hsa-mir-10a-5p 
+10.44 
LYPD6 2.526 3.097 2.526 2.240 
DLX1 4.285 4.081 4.401 4.285 
C1GALT1 2.159 2.047 2.159 2.336 
NEK7 1.837 1.782 2.511 1.837 
hsa-mir-6507-5p 
-5.37 
NDNF 4.047 4.047 3.505 4.078 
BTG2 -2.254 -1.616 -2.254 -2.277 
NEK7 1.837 1.782 2.511 1.837 
hsa-mir-629-3p 
+1.89 
TGFBI 2.715 2.369 2.947 2.715 
TFAP2A -3.635 -3.635 -3.410 -4.636 
hsa-mir-148a-3p 
+2.19 HOXC8 6.613 7.013 6.613 6.512 
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Once again, it can be stated that there is a similar correlation in the numerical values in 
the logFC for the three conditions. This correlation can be appreciated in the scatter plot 
of Figure 4.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In line with the way of proceeding with previous results, it is convenient to underline a 
small selection that due to scientific reasons should be dug deeper. The five miRNAs 
that were highlighted on Table 4.3 and Table 4.5, are included in these 13 miRNAs. 
And out of this five, just three of them show a correlation in alteration of the genes 
hsa-mir-556-5p 
-4.54 PTGER3 4.518 4.945 4.518 3.938 
hsa-mir-148a-5p 
+2.01 AFF2 5.905 5.999 5.360 5.905 
hsa-mir-195-3p 
+2.36 AR -3.316, -3.347 -3.316 -2.691 
hsa-mir-6842-3p 
-2.77 SLC2A1 -2.239 -2.140 -2.803 -2.239 
Figure 4.13. Scatter plot of the logFC of the genes from TABLE 4.9. 
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affected. It then would be interesting to look for the function and presence of those 
genes in the organism (Table 4.10). 
 
A curious remark is that the two miRNAs that are left out in this last filter belong to the 
mir10 family. This family seems to regulate a large amount of pathways [45] so the fact 
that the expression of the RNA target genes (out of the 227) is not inhibited in this case 
may suggest that their overexpression may not be related to the disease mechanism of 
the three genodermatoses. They might have appeared as important due to their great 
number of connections in the network but they could end up being out of study. 
Nevertheless, it would be a good idea to validate this hypothesis. 
 
TABLE 4.10. SELECTION OF MIRNAS-GENES BASED ON PREVIOUS RESULTS. 
 
 
 
 
 
 
 
 
miRNAs Target genes 
 
 
hsa-mir-195-5p 
 
 
BTG2, TLE4, C1orf226,  
SLC29A1, TFAP2A 
 
 
hsa-mir-615-3p 
 
SCARB1, PTPRU, 
SYPL2, CELSR1 
 
hsa-mir-129-5p 
 
 
L1CAM, ESR1, NR2F2 
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5. DISCUSSION 
 
It is becoming more and more evident that the richness of emerging data lies in the 
information researchers can extract from it and apply into scientific advances. This, in a 
large extent, also depends on the storage and organization of the data so as to be 
accessible and manageable. 
A new interdisciplinary science was born due to the necessity of handling the 
inconceivable amount of biological data that started to be generated, especially since the 
Human Genome Project and subsequent genomic sequence experiments [46]. 
Bioinformatics works as a powerful predictive tool in the phase before laboratory 
testing and validation. It takes into account a great diversity of parameters to try to 
recreate and model the reality as precisely as possible, and come up with a selective 
group of elements that has shown statistical significance of being involved in a 
particular process. Prioritization plays a fundamental role in directing a study to a more 
focused area, mainly at the beginning when a wide range of possibilities is open. 
5.1. Strategies employed in the prioritization step 
Different parameters can be taken into account when looking for preferential candidates 
for further research. Depending on the purpose of the study, greater weight will be given 
to one or other variable. Herein, the most common parameters that can be used to rank 
the miRNAs of biological interest are discussed: 
a) p-value: It is a value widely used in scientific experiments to discriminate data 
that does not satisfy the significant level imposed. Most times, the cut-off is 
made at p-value<0.05 so that the results with a p-value greater than 0.05 are 
ignored. This means that there exists a 95% of confidence that the given results 
are true. Nevertheless, there would still be a 5% of doubt that could give rise to 
false positives and false negatives. Accordingly, the corrected p-value, FDR, can 
be used with the same level of significance. The main difference is that FDR 
adjusts better to data in which many variables appear from few subjects. Of 
course this parameter provides an accurate filter but it could not be employed 
alone.  
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Furthermore, p-value and FDR depend a lot in the statistical power, this is, the 
number of samples vs. the number of variables and the effect of the causal 
relationship. The greater the sample size, the smaller the range of uncertainty 
with respect to the consistency of the data. One of the main drawbacks when 
studying rare diseases is the small number of subjects recruited. In this case, the 
sampling space was large enough to get valuable results. But, for example, the 
functional analysis could not be performed with the filtered network as the 
majority of pathways enriched appeared with a p-value=1 and therefore, they 
could not be considered significant. 
b) Fold change: It provides the biological meaning. The change is quantified in 
comparison with a benchmark. First, it must be assured that controls, in this case 
corresponding to healthy patients serve as correct and precise references. False 
negatives in this step would have baneful effects, even if the strategy is the most 
accurate and precise. In this case, the fold change could be a double-edged 
sword. A gene may be regulated by several miRNAs in such a way that, the 
contribution of up-regulated and down-regulated miRNAs at the same time 
could cancel each other and, as a result, find no significant differences with the 
expression profile of the healthy controls. Fold change would be then reliable in 
a one-to-one interaction but in a multiple contribution procedure, it may not be 
possible to detect easily the altered genes. Even with several hidden false 
negatives, the advantage of this parameter is the fact that the validity of positives 
is almost unquestionable. MiRNAs that show a considerable fold change are 
truly affecting the state of genes connected to them and that show the same level 
of difference from controls. 
c) Relevance in a miRNA-target genes network: Their position and connection 
within a network can say a lot about the influence of a node on other nodes or in 
the network in general. Degree and betweeness are useful for filtering and 
clustering and for giving explanation to the diversity of mismatches that diseases 
cause in an organism. Attending to this criterion, relevant nodes are more 
probable to be associated to disease but typically, a lot of nodes may pass these 
filters. Then, other tools will be needed for a more precise classification. 
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d) Target genes involved in a certain ontology/pathway of interest: Functional 
enrichment analysis serves to validate the participation of a specific component, 
function or process for which there is a still unclear evidence of its contribution. 
It is usually performed at the end when different proposals and hypotheses have 
been made. Therefore, the enrichment analysis is considered fruitful whenever 
results are expected. Databases that perform this type of selection usually return 
large amount of information. Hence, it is a risky option to go hypothesis-free 
through this analysis.  
e) Common results to other condtions: In this particular case, in which three 
diseases are being compared, a variable focused on similarity must be added. 
Any filtering made according to this parameter will be considered to be based on 
serious grounds. Indeed, the conclusions are desired to be certain for the three 
conditions, so the fact of appearing in just one of them is a qualifying criterion. 
In the end, we should be able to demonstrate the level of confidence in that our 
predicted results will adjust to reality. Traditionally, a combination of all parameters is 
performed [57-59].  
5.2.  Selection of relevant miRNA candidates for further research 
After all the aforesaid, miRNAs that have demonstrated to potentially influence on the 
development of RDEB, KS and XP will be summarized in this section, along with the 
supporting justifications. 
At the beginning, there were 18 miRNAs (section 4.1) that appeared altered in the three 
disorders and with a FDR < 0.05. Both reasons made them susceptible to be highly 
related with disease mechanisms and they are therefore the first conclusive candidates 
for further research. Nevertheless, as further research implies investment, the field of 
possibilities should be reduced to a more selected group. In this procedure, the other 
parameters will come into play. 
After the building of the network of miRNAs and target genes, 5 out of the previous 18 
miRNAs were highlighted due to their high degree: hsa-mir-615-3p, hsa-mir-195-5p, 
hsa-mir-129-5p, hsa-mir-10a-5p and hsa-mir-10b-5p (Table 4.1). A condition they 
maintained even after the application of the degree filter (Table 4.3). Furthermore, they 
45 
 
were also regulating the target genes with the highest degree (Table 4.2). All of this 
leads to the conclusion that these five miRNAs are the nodes that mainly sustain and 
control the entire network. If dysregulated, their impact will be notorious on almost all 
nodes and consequently it can explain the distorting phenotype of the genodermatoses. 
The five miRNAs are also behind the targeted genes that show the most significant 
enriched pathways. They are listed in order of degree in Table 4.5. The first position in 
all of them is occupied by hsa-mir-615-3p, with a considerable difference with respect 
to the second position. This miRNA also appears in the selection made according to the 
log fold change relationship with transcripts from the previous study. Therefore, it can 
be confirmed that hsa-mir-615-3p is the miRNA that shows greatest evidence of being 
responsible for controlling the disease module in RDEB, KS and XP.  
Regarding the other two highlighted miRNAs in relation to logFC, hsa-mir-129-5p has 
been related to squamous cell carcinoma in laryngeal tissue. MingHua et al. proved that 
has-mir-129-5p appeared significantly overexpressed in these type of carcinomas and its 
downregulation successfully reduced the progression and growth of the tumor [47]. On 
other side, hsa-mir-195-5p has been proposed as being involved in the inhibition of 
WNT signaling. And, as a result, responsible for causing loss-of-function in dermal 
papilla cells [48]. In the same way, these miRNAs may be behind the skin squamous 
cell carcinoma and loss of ability of skin components, two facts specially representative 
of the three conditions. 
 
5.3. Selection of relevant RNA candidates for further research 
Even though miRNAs are in the focus of the research, target genes that appear to be 
significant in the network also deserve to capture attention for future investigations. 
More than the ones with higher degree, a selection that spurs special interest 
corresponds to targeted genes that share connections with the outstanding miRNAs just 
mentioned above. Removing hsa-mir-129-5p from the group of five, the rest share 
interactions with FASN, HSPA1B, NR2C2, and KIAA0100.  
 FASN, whose official name is fatty acid synthase. It is the gene encoding a 
lipogenic enzyme that takes part in fatty oxidation pathways [49]. In cancer, this 
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pathway is remarkable. The reason is that cancerous cells are known to 
excessively consume glucose in aerobic conditions through glycolysis and 
generates precursors to activate the lipogenic switch [50]. However, in this case, 
the four miRNAs are upregulated so that the gene should be repressed.  
 HSPA1B, refers to a heat shock protein from the Hsp70 family. It mediates in 
the synthesis of proteins [49]. An analysis at protein level may give more 
information in this aspect. 
 NR2C2 encodes a nuclear receptor protein that acts as a transcription factor and 
it also have a cellular protective function against oxidative stress. Therefore, if it 
is repressed the protective function could be weakened and oxidative stress 
could have a stronger impact in the organism. A characteristic present in the 
three genodermatoses that could be justified in part by this particular gene.  
 KIAA0100: It has been found in breast carcinoma and seems to be related with 
miR-195 [49]. 
On other side, the functional enrichment analysis was performed on all genes of the 
global network. The results obtained in miRNet [38] along with the ones in REViGO 
[42] reveal clear variations in cellular senescence and oxidative imbalance, two 
processes that, to a large extent, justify the phenotypic profile of the three 
genodermatoses. 
Several studies have brought to the fore the similarities between senescent fibroblasts 
and cells from aged tissues[50] [51] .Cells start to slow down the division process until 
they are not able to grow and proliferate anymore. However, they still continue being 
active especially through the senescence-associated secretory phenotype, known as 
SASP, that produce modifications in the extracellular matrix. In association with this, 
detrimental effects such as tumorigenesis are originated (Figure 5.1) [52]. 
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Figure 5.1. Representation of the pro-tumorigenic microenvironment created from SASP of 
senescent cells. Source: [53] 
 
Literature also endorses the oxidative stress in dysfunctional skin [21][54]. Oxidative 
stress can be defined as the imbalance between reactive oxygen species (ROS) and the 
antioxidant cellular components. ROS are normally generated in the cell respiration 
process mainly at complex III in the electron transport chain (ETC) in mitochondria. As 
it happens in elderly people, a reduction in the rate of ETC involves an overproduction 
of ROS and pathways such as glycolysis are preferred instead [55]. Furthermore, the 
excessive build-up of ROS has been reported to be the cause for promoting cellular 
senescence [56]. Genes appearing as responsible for the enrichment of both processes 
are interesting to be thoroughly examined. 
Finally, the other group of genes that could be interesting to highlight are those that 
show an inverse correlation in the log fold change with the miRNA fold change (Table 
4.8). In order to make a relevant selection, all the genes that respond in opposite way to 
the dysregulation of their directed miRNAs may be explored for future lines. Among 
48 
 
them, it is worth underlining two downregulated genes linked to the upregulation of 
hsa-mir-615-3p: 
 PTPRU, it belongs to the protein tyrosine phosphatase (PTP) family. It acts as a 
signaling molecule in a quite variety of processes, particularly cell-to-cell 
interactions [49]. 
 CELSR1 is in charge of producing cadherin, an epidermal growth factor. 
Cellular growth and migration are modified in terms of its expression [49]. 
 
In summary, with the miRNAs obtained from RDEB, KS, XPC and healthy patients 
it has been possible to perform a bioinformatic analysis directed to highlight specific 
molecules and pathways that are predicted to be altered in the three genodermatoses. 
For the prioritization, it has been tried to make a balance of five parameters that are 
understood to be essential for the selection process. These are: p-value/FDR, fold 
change, relevance in networks, involvement in certain ontology/pathway and 
similarity. Finally, five miRNAs have been chosen to continue with research for 
demonstrating to be key molecules in the analysis. The final miRNA candidates for 
further validation are: 
- hsa-mir-615-3p, hsa-mir-195-5p and hsa-mir-129-5p with great 
expectations in justifying the phenotype of RDEB, KS and XPC. 
- hsa-mir-10a-5p and hsa-mir-10b-5p with doubts in their possible 
participation in the disease mechanism of RDEB, KS and XPC. 
With reference to the genes, FASN, HSPA1B, NR2C2, KIAA0100, PTPRU and 
CELSR1 have been concluded to take part, in some way, in the development of the 
diseases. But, maybe, the most relevant point of this thesis to the research is the fact that  
most miRNAs and genes, direct or indirectly, contribute to the oxidative stress, cellular 
senescence and tumorigenesis. Future research might be focused in clarifying the wiring 
diagram behind these outstanding pathways. 
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6. SOCIO-ECONOMIC IMPACT 
 
From a social point of view, this project can suppose an incredible advance on treating 
rare diseases. With the excuse that it affects a small percentage of population, 
sometimes they fall into neglect. But the truth is that hospitals and clinical sites are full 
of cases like the three genodermatoses under study. The only way to address with 
unknown diseases is biomedical research. Research projects are focused on giving 
answer to the two essential questions: what is going wrong in the organism and what 
can be done to correct it. And the response to these questions is highly related with the 
final aim of increasing as far as possible people’s quality of life.  
On the other hand, the economic impact could also be notorious. Given the predictive 
nature of bioinformatic analysis, costs and time can be both reduced. If the number of 
molecules to be validated decreases, it is evident that logistics and resources will be 
better economized. However, it is parallely necessary to improve the storage in 
databases and develop more precise algorithms so that the probability of success is 
considerably higher than the margin of error. The estimated budget to carry out the 
project in this thesis is summarized in Table 6.1.  
TABLE 6.1. ESTIMATED BUDGET FOR THE ACCOMPLISHMENT OF THE THESIS PROJECT 
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7. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Networks have clearly demonstrated to be useful in the interpretation of huge amounts 
of data thanks to its simplification in manageable and understandable ordered structures. 
With many biological processes still to be unveiled, knowledge on the general 
functioning of the organism can be at least described by defining their connections to 
other pathways. The emergence of a wide variety of network sciences has shifted public 
interest to a general insight of system biology. These are exactly the reasons why we 
have focused our efforts on knowing the impact of the eighteen common dysregulated 
miRNAs on a large scale. Although, afterwards, it was necessary to narrow down to 
specific nodes for retaining a small outstanding selection. 
The approach for prioritization of miRNAs and target genes made along this thesis has 
been based on repetitive presence when attending to different criteria. The greater the 
presence, the larger the probability of being key pieces in the control of disease 
modules. Nevertheless, with a deeper knowledge on statistics, a more precise ranking of 
miRNAs and target genes could have been achieved. The desired objective would be to 
create an automatic score formula in which all participating variables are taken into 
account and depending on the circumstances, they received a higher or lower weight. 
Several attempts have been made oriented to develop techniques and scores for 
prioritizing genes and miRNAs, trying to integrate statistical information without losing 
the biological meaning [57][58][59]. However, there is still a long way to achieve the 
appropriate score formula. 
As a conclusion, we can state that there is correlation in the results obtained with the 
phenotypic profile of the disease. It is possible to justify, in broad terms, the 
carcinogenic predisposition of RDEB, KS and XP through the cellular senescence and 
oxidative stress altered pathways. Nevertheless, it is important to recall that the 
performance of all the databases used along the analysis is based on the data that has 
been initially and progressively uploaded to create it. This means that networks are 
generated by algorithms that integrate the information we give with what the database 
already has. Hence, reliability of the results is not assured and depends greatly on the 
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completeness of the database itself. Hypotheses and premises should be sought 
previously in the literature to have the ability to interpret the quality of the networks. 
Framed in the translational research, the bioinformatics analysis performed has a 
potentially important therapeutic use through two immediately direct clinical 
applications: 
 The first one consists on the recognition of biomarkers that appear as pathogenic 
signatures of the disease. The diagnosis step determines in great part the success 
or failure of any treatment. Personalized medicine is the new trend that fights to 
be implemented in daily medical practice understanding the uniqueness of each 
patient to undergo its own personalized treatment according to the genome 
differences.  
In theranostics, molecular biomarkers serve to classify patients so that they 
receive the most effective treatment according to their condition.  
 The second one is focused on finding target molecules to which effective drug 
treatments could be directed. Surely, the disease mechanism behind the three 
genodermatoses is originated by a group of events happening at specific 
conditions, hence, a multiple origin. In this context, bioinformatics try to predict 
which are the key molecules that provoke the distortive cascade. By targeting 
those specific compounds, symptoms are expected to be largely palliated.  
Drug repurposing is a considerably recent trend that chases the use of already 
approved drugs for new targets. Both cost and time are substantially reduced 
given the enormous difficulties to launch new drugs into the market. In fact, it is 
estimated that less than 15% of chemical substances that initiate the drug 
development process are finally approved [60].In this sense, studies should try to 
look for drugs that can be reused to fight against the excessive oxidative stress. 
The key is to find a previous pathway that contributes to the oxidative stress and 
to which there is a known successful targeted treatment. 
To sum up, miRNAs have just opened a new door for the discovery of disease 
mechanisms and bioinformatics has proven to be an indispensable requirement for 
researchers to cross through it.   
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ANNEX 
Table with the 28 significant miRNAS in EDBR vs Healthy 
Gene_id logFC logCPM PValue FDR 
hsa-miR-10a-5p 8.824 15.506 5.040e-13 6.310e-10 
hsa-miR-10a-3p 8.590 6.421 1.107e-12 6.931e-10 
hsa-miR-556-5p -4.536 -1.136 1.383e-11 5.772e-09 
hsa-miR-6507-5p -4.779 -2.072 5.103e-08 1.597e-05 
hsa-miR-6842-3p -2.425 1.260 7.527e-08 1.885e-05 
hsa-miR-195-3p 2.902 4.292 3.217e-07 6.712e-05 
hsa-miR-556-3p -3.859 -2.270 7.267e-07 1.300e-04 
hsa-miR-129-5p 3.604 4.105 1.863e-06 2.915e-04 
hsa-miR-129-2-3p 2.975 2.725 4.151e-06 5.774e-04 
hsa-miR-29b-2-5p -2.150 0.624 7.285e-06 8.440e-04 
hsa-miR-10b-5p 4.379 15.553 7.415e-06 8.440e-04 
hsa-miR-29c-5p -1.901 2.887 1.737e-05 1.813e-03 
hsa-miR-29c-3p -2.172 7.219 2.798e-05 2.694e-03 
hsa-miR-10b-3p 4.185 4.142 3.675e-05 3.286e-03 
hsa-miR-1295a -3.015 -0.935 6.489e-05 5.416e-03 
hsa-miR-4488 -2.192 -1.061 7.257e-05 5.679e-03 
hsa-miR-615-3p 3.925 9.194 8.503e-05 6.262e-03 
hsa-miR-148a-5p 2.112 6.922 1.078e-04 7.499e-03 
hsa-miR-146b-5p -1.976 9.142 1.146e-04 7.552e-03 
hsa-miR-615-5p 4.028 4.577 2.479e-04 1.531e-02 
hsa-miR-874-5p -1.612 1.284 2.686e-04 1.531e-02 
hsa-miR-497-5p 2.303 7.525 2.690e-04 1.531e-02 
hsa-miR-195-5p 2.555 7.207 5.443e-04 2.931e-02 
hsa-miR-935 -2.624 -1.623 5.618e-04 2.931e-02 
hsa-miR-629-3p 1.973 1.196 6.219e-04 3.011e-02 
hsa-miR-148a-3p 2.069 12.783 6.253e-04 3.011e-02 
hsa-miR-1468-5p -2.008 4.891 6.669e-04 3.092e-02 
 
  
 
Table with the 99 significant miRNAs in KS vs Healthy 
Gene_id logFC logCPM PValue FDR 
hsa-miR-1291 5.774 2.764 1.049e-17 1.011e-14 
hsa-miR-10a-5p 10.496 16.335 2.217e-17 1.069e-14 
hsa-miR-1260a 5.360 1.685 1.503e-15 4.830e-13 
hsa-miR-10a-3p 9.535 6.274 3.761e-13 9.064e-11 
hsa-miR-483-3p -6.817 2.232 6.627e-13 1.278e-10 
hsa-miR-483-5p -7.343 2.243 1.383e-12 2.221e-10 
hsa-miR-556-5p -6.282 -0.557 4.896e-12 6.742e-10 
hsa-miR-3607-5p 4.149 0.746 8.124e-11 9.789e-09 
hsa-miR-1295a -4.676 -0.373 2.420e-09 2.593e-07 
hsa-miR-1468-5p -3.589 5.281 3.161e-08 3.047e-06 
hsa-miR-129-5p 3.582 3.331 4.865e-08 4.263e-06 
hsa-miR-129-2-3p 3.237 2.552 1.004e-07 7.597e-06 
hsa-miR-1247-5p -5.513 0.273 1.025e-07 7.597e-06 
hsa-miR-3605-3p -2.427 3.054 1.662e-07 1.144e-05 
hsa-miR-7974 2.918 4.238 3.096e-07 1.989e-05 
hsa-miR-6842-3p -2.770 1.902 6.803e-07 3.773e-05 
hsa-miR-10b-5p 5.137 15.669 7.019e-07 3.773e-05 
hsa-miR-29c-3p -2.119 7.451 7.044e-07 3.773e-05 
hsa-miR-148a-3p 2.276 12.498 1.562e-06 7.927e-05 
hsa-miR-3615 -2.124 6.401 4.902e-06 2.363e-04 
hsa-miR-137 2.503 5.253 5.442e-06 2.498e-04 
hsa-miR-195-5p 2.936 6.994 6.427e-06 2.816e-04 
hsa-miR-6507-5p -5.372 -1.443 7.726e-06 3.108e-04 
hsa-miR-3184-3p -1.852 9.164 7.739e-06 3.108e-04 
hsa-miR-31-3p 1.948 7.390 1.090e-05 4.202e-04 
hsa-miR-561-5p -1.929 5.927 1.152e-05 4.271e-04 
hsa-miR-3529-3p 2.033 3.652 1.671e-05 5.965e-04 
hsa-miR-4767 2.362 -0.0198 1.929e-05 6.641e-04 
hsa-miR-10b-3p 4.932 4.236 2.146e-05 7.088e-04 
hsa-miR-4517 2.388 -0.114 2.206e-05 7.088e-04 
  
hsa-miR-4653-5p 3.374 -1.156 2.941e-05 9.145e-04 
hsa-miR-221-5p 1.722 10.263 4.374e-05 1.318e-03 
hsa-miR-29b-2-5p -2.095 1.059 5.826e-05 1.702e-03 
hsa-miR-877-5p -1.821 5.758 6.856e-05 1.944e-03 
hsa-miR-142-5p 3.386 2.908 8.156e-05 2.162e-03 
hsa-miR-149-5p -1.864 8.024 8.172e-05 2.162e-03 
hsa-miR-5701 -6.849 -1.448 8.297e-05 2.162e-03 
hsa-miR-155-3p 3.482 -1.475 1.150e-04 2.918e-03 
hsa-miR-142-3p 3.617 1.494 1.246e-04 3.081e-03 
hsa-miR-181a-5p -1.970 13.824 1.466e-04 3.533e-03 
hsa-let-7i-3p 1.954 6.066 1.542e-04 3.625e-03 
hsa-miR-548ab -1.939 1.601 2.066e-04 4.735e-03 
hsa-miR-133a-3p -3.795 1.366 2.112e-04 4.735e-03 
hsa-miR-328-3p -1.558 5.970 2.410e-04 5.281e-03 
hsa-miR-128-3p -1.500 8.466 2.565e-04 5.495e-03 
hsa-miR-4521 2.209 4.993 2.626e-04 5.504e-03 
hsa-miR-624-5p 2.134 -0.376 2.851e-04 5.847e-03 
hsa-miR-1305 2.312 2.268 3.011e-04 6.047e-03 
hsa-miR-100-3p 1.602 7.980 3.220e-04 6.336e-03 
hsa-miR-629-3p 1.893 0.756 3.352e-04 6.463e-03 
hsa-miR-98-3p -1.439 4.571 3.613e-04 6.830e-03 
hsa-miR-6784-3p -2.060 -0.052 4.059e-04 7.525e-03 
hsa-miR-1247-3p -6.422 -1.805 4.445e-04 8.085e-03 
hsa-miR-148a-5p 2.012 6.647 4.925e-04 8.792e-03 
hsa-miR-887-3p -1.571 7.305 5.145e-04 9.019e-03 
hsa-miR-454-5p -1.491 3.088 5.389e-04 9.276e-03 
hsa-miR-326 -1.541 3.472 5.721e-04 9.564e-03 
hsa-miR-556-3p -3.428 -1.918 5.754e-04 9.564e-03 
hsa-miR-7-5p 2.166 0.287 6.960e-04 1.137e-02 
hsa-miR-145-5p 1.770 10.846 7.213e-04 1.159e-02 
hsa-miR-6868-3p -2.724 -0.975 7.424e-04 1.173 e-02 
hsa-miR-6737-3p -1.711 0.259 7.964e-04 1.238 e-02 
hsa-miR-6769b-3p -1.581 0.986 8.849e-04 1.354 e-02 
  
hsa-miR-19b-1-5p 1.875 -0.054 9.072e-04 1.367 e-02 
hsa-miR-496 1.472 3.573 9.418e-04 1.397 e-02 
hsa-miR-195-3p 2.011 3.061 1.012e-03 1.478 e-02 
hsa-miR-1972 1.740 0.585 1.148e-03 1.652 e-02 
hsa-miR-135b-5p 2.387 0.980 1.179e-03 1.671 e-02 
hsa-miR-1268a 1.630 2.690 1.202e-03 1.679 e-02 
hsa-miR-6716-3p -1.554 1.501 1.219e-03 1.679 e-02 
hsa-miR-144-5p -2.106 -0.822 1.414e-03 1.910 e-02 
hsa-miR-3677-3p 1.400 2.773 1.426e-03 1.910 e-02 
hsa-miR-615-3p 3.246 7.932 1.502e-03 1.983 e-02 
hsa-miR-423-3p -1.340 11.372 1.523e-03 1.984 e-02 
hsa-miR-1910-5p -1.637 0.666 1.549e-03 1.991 e-02 
hsa-miR-5683 3.181 -0.348 1.585e-03 2.011 e-02 
hsa-miR-605-5p 1.655 0.935 1.665e-03 2.085 e-02 
hsa-miR-3152-5p 2.936 3.544 1.835e-03 2.242 e-02 
hsa-miR-196b-5p -1.531 9.238 1.842e-03 2.242 e-02 
hsa-miR-573 2.556 -1.061 1.861e-03 2.242 e-02 
hsa-miR-130b-5p -1.310 5.899 1.200e-03 2.380 e-02 
hsa-miR-4803 2.149 -0.995 2.079e-03 2.444 e-02 
hsa-miR-2116-3p -1.470 1.469 2.124e-03 2.467 e-02 
hsa-miR-33b-5p -1.445 3.862 2.184e-03 2.506 e-02 
hsa-miR-668-3p -1.428 2.642 2.447e-03 2.775 e-02 
hsa-miR-6750-3p -2.200 -1.509 2.513e-03 2.817 e-02 
hsa-miR-3152-3p 2.117 -1.325 2.664e-03 2.952 e-02 
hsa-miR-4731-3p 2.260 -1.141 2.792e-03 3.059 e-02 
hsa-miR-423-5p -1.194 9.065 3.026e-03 3.278 e-02 
hsa-miR-106b-3p -1.241 6.007 3.327e-03 3.531 e-02 
hsa-miR-153-3p -2.482 2.443 3.350e-03 3.531 e-02 
hsa-miR-34c-3p 1.376 3.152 3.370e-03 3.531 e-02 
hsa-miR-365a-3p 1.176 7.691 3.514e-03 3.642 e-02 
hsa-miR-6824-3p -1.627 -0.293 3.600e-03 3.691 e-02 
hsa-miR-29c-5p -1.312 3.440 3.797e-03 3.853 e-02 
hsa-miR-3157-5p 2.022 -0.851 3.860e-03 3.876 e-02 
  
hsa-miR-656-5p 1.817 -0.913 4.191e-03 4.165 e-02 
hsa-miR-3613-3p 1.315 2.188 4.278e-03 4.208 e-02 
hsa-miR-1254 -1.345 1.726 4.758e-03 4.633 e-02 
 
 
Table with the 148 significant miRNAs in XPC vs Healthy 
Gene_id logFC logCPM PValue FDR 
hsa-miR-10a-5p 10.442 16.236 4.086e-74 3.641e-71 
hsa-miR-10a-3p 9.483 6.258 1.155e-44 5.144e-42 
hsa-miR-1260a 7.239 3.462 1.617e-23 4.803e-21 
hsa-miR-6087 6.211 2.099 2.032e-14 4.526e-12 
hsa-miR-129-5p 3.999 3.675 2.297e-13 4.093e-11 
hsa-miR-129-2-3p 3.639 2.870 4.422e-13 6.567e-11 
hsa-miR-195-5p 3.145 7.139 2.842e-10 3.618e-08 
hsa-miR-1295a -5.668 -0.282 2.501e-09 2.785e-07 
hsa-miR-1291 5.148 2.109 1.005e-08 9.951e-07 
hsa-miR-6842-3p -3.317 1.830 3.823e-08 3.186e-06 
hsa-miR-10b-5p 5.152 15.644 3.934e-08 3.186e-06 
hsa-miR-155-3p 4.731 -0.526 5.253e-08 3.900e-06 
hsa-miR-1468-5p -3.251 5.261 1.197e-07 8.207e-06 
hsa-miR-137 2.870 5.524 2.004e-07 1.266e-05 
hsa-let-7i-3p 2.504 6.472 2.300e-07 1.266e-05 
hsa-miR-5683 5.262 1.388 2.316e-07 1.266e-05 
hsa-miR-556-5p -4.168 -0.377 2.493e-07 1.266e-05 
hsa-miR-146a-5p 3.763 7.167 2.557e-07 1.266e-05 
hsa-miR-3607-5p 3.859 0.432 6.783e-07 3.181e-05 
hsa-miR-148a-3p 2.188 12.377 8.616e-07 3.838e-05 
hsa-miR-147b 3.088 2.324 1.132e-06 4.802e-05 
hsa-miR-548ab -2.636 1.483 1.697e-06 6.873e-05 
hsa-miR-877-5p -2.057 5.661 3.409e-06 1.321e-04 
hsa-miR-4454 2.278 3.991 4.725e-06 1.754e-04 
hsa-miR-10b-3p 4.989 4.256 4.996e-06 1.781e-04 
hsa-miR-100-3p 1.974 8.221 5.690e-06 1.950e-04 
  
hsa-miR-195-3p 2.365 3.304 6.012e-06 1.984e-04 
hsa-miR-3605-3p -1.940 3.106 1.082e-05 3.442e-04 
hsa-miR-3117-3p 2.637 4.832 1.236e-05 3.798e-04 
hsa-miR-19b-1-5p 2.456 0.334 1.423e-05 4.221e-04 
hsa-miR-142-5p 2.802 2.358 1.468e-05 4.221e-04 
hsa-miR-483-5p -4.169 2.298 2.110e-05 5.876e-04 
hsa-miR-1247-5p -4.264 0.381 2.401e-05 6.481e-04 
hsa-miR-7974 2.170 3.551 2.798e-05 7.331e-04 
hsa-miR-146a-3p 6.520 0.908 3.530e-05 8.987e-04 
hsa-miR-15a-3p 2.503 -0.058 3.795e-05 9.392e-04 
hsa-miR-3615 -1.724 6.436 3.980e-05 9.585e-04 
hsa-miR-4524a-5p 2.469 0.042 4.376e-05 1.026e-03 
hsa-miR-3184-3p -1.577 9.179 4.560e-05 1.042e-03 
hsa-miR-129-1-3p 5.018 -0.896 4.733e-05 1.054e-03 
hsa-miR-3614-5p 4.423 1.783 5.032e-05 1.078e-03 
hsa-miR-155-5p 1.753 9.458 5.080e-05 1.078e-03 
hsa-miR-4488 -3.355 -0.471 5.820e-05 1.206e-03 
hsa-miR-4473 -2.102 0.712 6.801e-05 1.377e-03 
hsa-miR-891a-5p 7.110 -0.711 7.145e-05 1.415e-03 
hsa-miR-183-5p 3.802 3.166 7.650e-05 1.482e-03 
hsa-miR-6507-5p -6.470 -1.239 8.237e-05 1.561e-03 
hsa-miR-624-5p 2.423 -0.209 9.000e-05 1.671e-03 
hsa-miR-561-5p -1.840 5.899 9.521e-05 1.731e-03 
hsa-miR-4517 2.201 -0.295 1.018e-04 1.814e-03 
hsa-miR-196b-5p -1.569 9.180 1.115e-04 1.948e-03 
hsa-miR-142-3p 2.619 0.620 1.261e-04 2.160e-03 
hsa-miR-454-5p -1.637 3.014 1.286e-04 2.162e-03 
hsa-miR-1908-3p -2.026 0.945 1.415e-04 2.334e-03 
hsa-miR-668-3p -1.885 2.501 1.965e-04 3.183e-03 
hsa-miR-615-3p 3.474 8.101 2.180e-04 3.468e-03 
hsa-miR-3529-3p 1.677 3.325 2.483e-04 3.882e-03 
hsa-miR-615-5p 3.663 3.620 2.771e-04 4.257e-03 
hsa-miR-21-3p 1.419 12.740 3.466e-04 5.234e-03 
  
hsa-miR-4773 1.970 -0.0757 3.713e-04 5.513e-03 
hsa-miR-6737-3p -2.056 0.219 4.175e-04 6.098e-03 
hsa-miR-98-3p -1.477 4.517 4.295e-04 6.173e-03 
hsa-miR-146b-3p -2.345 5.170 4.685e-04 6.625e-03 
hsa-miR-874-5p -1.858 1.408 4.786e-04 6.654e-03 
hsa-miR-326 -1.874 3.356 4.891e-04 6.654e-03 
hsa-miR-31-3p 1.421 6.942 4.929e-04 6.654e-03 
hsa-miR-34c-3p 1.744 3.375 5.020e-04 6.676e-03 
hsa-miR-20a-5p 1.370 8.011 5.965e-04 7.816e-03 
hsa-miR-487b-3p -1.321 7.471 6.156e-04 7.933e-03 
hsa-miR-486-3p -1.808 3.338 6.257e-04 7.933e-03 
hsa-miR-887-3p -1.518 7.268 6.321e-04 7.933e-03 
hsa-miR-3613-3p 1.528 2.291 7.211e-04 8.924e-03 
hsa-miR-1268a 1.681 2.677 7.725e-04 9.428e-03 
hsa-miR-149-5p -1.478 8.066 8.263e-04 9.949e-03 
hsa-miR-19a-5p 2.202 -0.506 9.320e-04 1.107e-02 
hsa-miR-549a -1.617 6.501 1.017e-03 1.192e-02 
hsa-miR-431-3p -1.369 3.480 1.090e-03 1.261e-02 
hsa-miR-4767 2.370 -0.080 1.157e-03 1.322e-02 
hsa-miR-6868-3p -2.539 -0.829 1.183e-03 1.334e-02 
hsa-miR-29b-2-5p -1.709 1.138 1.226e-03 1.358e-02 
hsa-miR-3613-5p 1.427 4.489 1.235e-03 1.358e-02 
hsa-miR-1299 2.329 1.775 1.286e-03 1.398e-02 
hsa-miR-6747-3p -2.775 -1.139 1.305e-03 1.401e-02 
hsa-miR-328-3p -1.237 6.010 1.607e-03 1.704e-02 
hsa-miR-16-1-3p 1.630 0.855 1.719e-03 1.802e-02 
hsa-miR-424-5p 1.460 10.492 1.743e-03 1.806e-02 
hsa-miR-1233-3p -3.758 -1.677 1.870e-03 1.915e-02 
hsa-miR-2116-3p -1.627 1.414 1.915e-03 1.939e-02 
hsa-miR-128-3p -1.219 8.496 1.999e-03 2.001e-02 
hsa-miR-585-5p 1.921 2.799 2.038e-03 2.018e-02 
hsa-miR-944 6.216 -1.562 2.108e-03 2.062e-02 
hsa-miR-483-3p -2.997 2.372 2.129e-03 2.062e-02 
  
hsa-miR-5701 -4.472 -1.201 2.164e-03 2.074e-02 
hsa-miR-548h-3p 1.768 -0.383 2.236e-03 2.120e-02 
hsa-miR-3194-5p 3.070 -1.733 2.352e-03 2.195e-02 
hsa-miR-503-3p 1.662 2.792 2.365e-03 2.195e-02 
hsa-miR-584-5p -1.178 5.978 2.488e-03 2.263e-02 
hsa-miR-1270 1.620 0.654 2.498e-03 2.263e-02 
hsa-miR-4524a-3p 2.686 -1.151 2.515e-03 2.263e-02 
hsa-miR-6787-3p -2.832 -1.038 2.566e-03 2.287e-02 
hsa-miR-548t-3p 1.652 0.229 2.616e-03 2.308e-02 
hsa-miR-181a-5p -1.479 13.887 2.711e-03 2.368e-02 
hsa-miR-486-5p -1.578 9.533 2.776e-03 2.340e-02 
hsa-miR-1296-3p 1.947 -0.787 2.800e-03 2.340e-02 
hsa-miR-744-5p -1.171 7.878 2.866e-03 2.420 e-02 
hsa-miR-431-5p -1.139 7.452 2.920e-03 2.420e-02 
hsa-miR-133a-3p -2.232 1.544 2.928e-03 2.420e-02 
hsa-miR-423-3p -1.118 11.388 2.933e-03 2.420e-02 
hsa-miR-548z 1.907 0.105 3.125e-03 2.554e-02 
hsa-miR-450a-1-3p 1.921 -0.382 3.414e-03 2.765e-02 
hsa-miR-629-3p 1.511 0.438 3.446e-03 2.766e-02 
hsa-miR-485-5p -1.145 5.607 3.573e-03 2.842e-02 
hsa-miR-1273g-3p 1.661 0.763 3.631e-03 2.863e-02 
hsa-miR-598-3p -1.566 3.942 3.663e-03 2.863e-02 
hsa-miR-7641 1.958 1.882 3.854e-03 2.986e-02 
hsa-miR-543 -1.128 5.442 4.052e-03 3.112e-02 
hsa-miR-181b-5p -1.385 10.516 4.124e-03 3.140e-02 
hsa-miR-6720-3p -1.790 0.367 4.215e-03 3.183e-02 
hsa-miR-7706 -1.129 5.186 4.336e-03 3.237e-02 
hsa-miR-1252-5p -3.811 -1.081 4.379e-03 3.237e-02 
hsa-miR-140-5p 1.180 6.202 4.396e-03 3.237e-02 
hsa-miR-221-5p 1.091 9.758 4.487e-03 3.277e-02 
hsa-miR-548am-5p 1.678 0.846 4.563e-03 3.306e-02 
hsa-miR-34b-5p 1.315 5.898 4.635e-03 3.331 e-02 
hsa-miR-148a-5p 1.530 6.224 5.180e-03 3.692 e-02 
  
hsa-miR-27a-5p 1.102 6.044 5.315e-03 3.758 e-02 
hsa-miR-708-3p 1.873 5.737 5.375e-03 3.771 e-02 
hsa-miR-3607-3p -1.284 4.756 5.485e-03 3.818 e-02 
hsa-miR-374a-5p 1.135 6.558 5.543e-03 3.829 e-02 
hsa-let-7d-5p -1.154 9.847 5.708e-03 3.891 e-02 
hsa-miR-4707-3p -2.406 -0.957 5.743e-03 3.891 e-02 
hsa-miR-190a-5p 1.155 7.091 5.764e-03 3.891 e-02 
hsa-miR-1254 -1.364 1.700 6.095e-03 4.060 e-02 
hsa-miR-1972 1.512 0.377 6.106e-03 4.060 e-02 
hsa-miR-4521 -1.795 2.843 6.193e-03 4.087 e-02 
hsa-miR-432-5p -1.086 6.448 6.298e-03 4.126 e-02 
hsa-miR-18a-5p 1.135 4.900 6.548e-03 4.259 e-02 
hsa-miR-30c-2-3p -1.086 4.818 7.089e-03 4.554 e-02 
hsa-miR-106a-5p 1.507 -0.307 7.105e-03 4.554 e-02 
hsa-miR-655-5p -1.560 -0.367 7.289e-03 4.639 e-02 
hsa-miR-145-5p 1.205 10.385 7.524e-03 4.752 e-02 
hsa-miR-1305 1.537 1.634 7.611e-03 4.752 e-02 
hsa-miR-874-3p -1.231 4.357 7.627e-03 4.752 e-02 
hsa-miR-374a-3p 1.046 8.234 7.849e-03 4.799 e-02 
hsa-miR-3120-3p 1.233 3.528 7.853e-03 4.799 e-02 
hsa-miR-3157-5p 1.941 -0.923 7.863e-03 4.799 e-02 
hsa-miR-675-5p 4.852 -1.038 8.154e-03 4.942 e-02 
hsa-miR-1180-3p -1.086 5.860 8.253e-03 4.968e-02 
 
